This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy.
Everyone wants the best treatment available when it comes to cancer, breast cancer is no different. This week the FDA pulled its accelerated approval of Avastin for women with HER2-negative metastatic breast cancer who have not undergone chemotherapy. Avastin is still available for other types of cancer but because it is no longer approved for breast cancer insurance companies will not cover the approximately $8000.00 per month it costs. This puts breast cancer treatment out of reach for many women who say this was working for them.
Regulatory T cell alterations in early pregnancy linked to spontaneous preterm labor
February 18th 2025A recent study reveals that specific Treg subpopulation changes in the first trimester may contribute to spontaneous preterm labor, shedding light on the role of immune regulation in pregnancy outcomes.
Read More
Late third-trimester ultrasound accurately predicts large for gestational age births
February 17th 2025A new study confirms that estimating fetal weight with ultrasound between 35 to 38 weeks’ gestation strongly predicts large for gestational age births, helping guide clinical management decisions.
Read More